The problem is that peptides are usually too small and too easily digested by digestive enzymes. We can ‘cut and paste’ genes of interest using a LEGO-like platform technology to produce multi-domain fusion proteins capable of being orally administered. Using powerful bioinformatics search engines, we select compelling candidate genes with the result of a higher than 50% ‘hit rate’. We now possess an almost unlimited capability of producing new antiviral and anticancer candidates using our novel proprietary platform as a drug discovery engine that will be soon supported by an in house- GMP manufacturing facility for clinical batches.
RetroMAD1 is a 41.2 kDa Chimeric Anti Microbial (ChAMP) .By using Super Critical Fluid Drying (SCFD) RetroMAD1 can also be turned into a free flowing micronized powder form in addition to its normal liquid format.
In our trials for RetroMAD1 as a broad spectrum antiviral, we have indeed shown that RetroMAD1 exhibits antiviral properties in viral infections in various species. From shrimp viruses in aqua-culture (completely stopping mortality); to improving survival and quality of life of our companion animals from Feline Immunodeficiency (FIV) Feline Leukemia Virus (FeLV) and Canine Parvovirus 2, (with symptomatic recovery rates as high as 70 — 80%); to in vitro testing against human viruses such as Herpes Simplex Virus- 1&2 and all 4 Dengue Virus serotypes (showing viral reduction to as high as 100% in HSV2 and DENV2&4). Our drug has shown promising potential and opens the door for many more future treatment possibilities including Chikungunya. HIV-1 humanized mouse trials are with the National Institutes of Health (USA) will be done in 2014.